Cipla, the fifth largest Indian pharma company with net sales of Rs. 10,800 crore plus, has presented a new respiratory inhaler Synchrobreathe (SB) at the South Africa Thoracic Society (SATS) conference in Cape Town, South Africa. SB is a state-of the art breath-actuated inhaler which will bring relief to millions of patients with obstructive airway disease (OAD), asthma and COPD. Cipla has been at the forefront of innovation for inhalation therapy over the last 40 years.

SB will be welcomed by patients with OAD globally as it is very simple to use and eliminates coordination challenges, the inspiratory flow required to trigger the inhaler mechanism is low and it is a breath-actuated inhaler (BAI) with built-in dose counter which allows patients to track doses, thereby encouraging patient compliance.  

Frank Pieters, global head of respiratory for Cipla, said, “Simple and intuitive, Synchrobreathe is an innovation in managing respiratory disease. SB is attractive for patients as the inhaler is easy to use effectively. Equally importantly, SB will help cut the time healthcare providers need to spend to train patients in correct inhaler use. With this simple inhaler, the healthcare professional knows the patient will be able to use it easily and get the full benefit from every dose.”

Paul Miller, CEO Cipla Medpro, South Africa added, “South Africa has amongst the highest asthma mortality rates in the world. As a leading company in the area of respiratory health in South Africa, we are proud to announce the development of this innovation for the first time to the medical community at the SATS congress. Synchrobreathe will definitely make patients' lives easier in managing their obstructive airway disease. Synchrobreathe is in line with Cipla's commitment to bring innovative products and inhalers to best fit physicians' and patients' needs, thereby advancing healthcare for all Synchrobreathe is expected to reach the market in the current year.”

Currently, Cipla respiratory products are available in over 100 countries. Cipla offers the world's largest portfolio of inhalation products with 27 molecules and combinations across a range of inhalers, to suit individual patients needs. Cipla has end-to-end capability across respiratory care covering the value chain from API, formulation, inhalers development and manufacturing to medical and patient education.